Header Logo

Connection

CHAD CREIGHTON to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications CHAD CREIGHTON has written about Prostatic Neoplasms.
CHAD CREIGHTON
Connection Strength
3.318
Prostatic Neoplasms
  1. Comparative and integrative analysis of transcriptomic and epigenomic-wide DNA methylation changes in African American prostate cancer. Epigenetics. 2023 12; 18(1):2180585.
    View in: PubMed
    Score: 0.469
  2. Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors. PLoS One. 2008 Mar 19; 3(3):e1816.
    View in: PubMed
    Score: 0.158
  3. A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers. BMC Genomics. 2007 Jun 28; 8:199.
    View in: PubMed
    Score: 0.150
  4. Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer. Oncogene. 2025 Dec; 44(50):4868-4877.
    View in: PubMed
    Score: 0.135
  5. Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth. Oncogene. 2023 08; 42(32):2428-2438.
    View in: PubMed
    Score: 0.114
  6. Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity. Nat Commun. 2022 11 11; 13(1):6828.
    View in: PubMed
    Score: 0.109
  7. Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130. Oncogene. 2022 Feb; 41(9):1309-1323.
    View in: PubMed
    Score: 0.103
  8. CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. Neoplasia. 2021 11; 23(11):1147-1165.
    View in: PubMed
    Score: 0.101
  9. YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. Oncogene. 2021 04; 40(13):2407-2421.
    View in: PubMed
    Score: 0.097
  10. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. J Clin Invest. 2021 02 15; 131(4).
    View in: PubMed
    Score: 0.097
  11. Neuropeptide Y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance. Prostate. 2021 01; 81(1):58-71.
    View in: PubMed
    Score: 0.094
  12. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat Commun. 2020 08 27; 11(1):4279.
    View in: PubMed
    Score: 0.094
  13. The Sca-1+ and Sca-1- mouse prostatic luminal cell lineages are independently sustained. Stem Cells. 2020 11; 38(11):1479-1491.
    View in: PubMed
    Score: 0.093
  14. MicroRNAs as prognostic markers in prostate cancer. Prostate. 2019 02; 79(3):265-271.
    View in: PubMed
    Score: 0.082
  15. Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGF?RIII-p38MAPK-pS249/T252RB Pathway. Cancer Res. 2018 06 01; 78(11):2911-2924.
    View in: PubMed
    Score: 0.079
  16. Influence of the neural microenvironment on prostate cancer. Prostate. 2018 Feb; 78(2):128-139.
    View in: PubMed
    Score: 0.077
  17. RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression. Cancer Res. 2017 08 15; 77(16):4247-4257.
    View in: PubMed
    Score: 0.075
  18. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway. Oncotarget. 2017 Feb 07; 8(6):10145-10160.
    View in: PubMed
    Score: 0.073
  19. MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer. Cancer Res. 2016 11 01; 76(21):6290-6298.
    View in: PubMed
    Score: 0.071
  20. Neuronal Trans-Differentiation in Prostate Cancer Cells. Prostate. 2016 10; 76(14):1312-25.
    View in: PubMed
    Score: 0.070
  21. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. J Clin Invest. 2016 07 01; 126(7):2626-41.
    View in: PubMed
    Score: 0.070
  22. Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. Nat Commun. 2016 04 25; 7:11418.
    View in: PubMed
    Score: 0.069
  23. FGF23 promotes prostate cancer progression. Oncotarget. 2015 Jul 10; 6(19):17291-301.
    View in: PubMed
    Score: 0.066
  24. Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression. Cancer Invest. 2015 Jul; 33(6):251-8.
    View in: PubMed
    Score: 0.065
  25. Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis. Oncotarget. 2015 Mar 20; 6(8):6281-94.
    View in: PubMed
    Score: 0.064
  26. Stromal TGF-? signaling induces AR activation in prostate cancer. Oncotarget. 2014 Nov 15; 5(21):10854-69.
    View in: PubMed
    Score: 0.063
  27. FGFR1-WNT-TGF-? signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res. 2014 Jan 15; 74(2):609-20.
    View in: PubMed
    Score: 0.059
  28. A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis. Oncogene. 2014 Jun 12; 33(24):3099-108.
    View in: PubMed
    Score: 0.057
  29. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. 2013 Apr 15; 73(8):2551-62.
    View in: PubMed
    Score: 0.056
  30. COUP-TFII inhibits TGF-?-induced growth barrier to promote prostate tumorigenesis. Nature. 2013 Jan 10; 493(7431):236-40.
    View in: PubMed
    Score: 0.055
  31. Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells. PLoS One. 2011; 6(7):e21417.
    View in: PubMed
    Score: 0.050
  32. FGFR-4 Arg?88 enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. Clin Cancer Res. 2011 Jul 01; 17(13):4355-66.
    View in: PubMed
    Score: 0.049
  33. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.
    View in: PubMed
    Score: 0.047
  34. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 2010 Mar 01; 70(5):1906-15.
    View in: PubMed
    Score: 0.045
  35. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res. 2009 Jun 15; 15(12):3979-89.
    View in: PubMed
    Score: 0.043
  36. Genomic profiling of prostate cancers from African American men. Neoplasia. 2009 Mar; 11(3):305-12.
    View in: PubMed
    Score: 0.042
  37. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 2007 Nov; 12(5):419-31.
    View in: PubMed
    Score: 0.038
  38. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008 Mar 13; 27(12):1788-93.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.